Saad Usmani to Receptors, Antigen, T-Cell
This is a "connection" page, showing publications Saad Usmani has written about Receptors, Antigen, T-Cell.
Connection Strength
0.272
-
Nath K, Mailankody S, Usmani SZ. The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies. Hematol Oncol Clin North Am. 2023 12; 37(6):1201-1214.
Score: 0.173
-
Jurgens EM, Mitra S, Herrera K, Nemirovsky D, Bready B, Derkach A, Hosszu K, McAvoy D, Firestone RS, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Merz M, Maura F, Giralt SA, Shah GL, Landau HJ, Scordo M, Kotchetkov IS, Santomasso BD, Park J, Leslie CS, Usmani SZ, Perica K, Mailankody S. Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma. Sci Transl Med. 2026 Jul 29; 18(860):eaed0039.
Score: 0.054
-
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD, Kumar S, Martin T. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 08; 25(8):e374-e387.
Score: 0.046